Immuron Business Update: Letter to Shareholders
June 22, 2023 06:00 ET
|
Immuron Limited
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
January 17, 2023 07:10 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
July 07, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
April 11, 2019 10:00 ET
|
Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
January 31, 2018 09:30 ET
|
Immuron Limited
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...
Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
August 09, 2017 08:30 ET
|
Immuron Limited
Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...